LXRX vs. NVAX, OPK, GERN, RGLS, MYGN, ZBIO, EBS, RIGL, XOMA, and VNDA
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs. Its Competitors
Lexicon Pharmaceuticals (NASDAQ:LXRX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Lexicon Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.
In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Novavax. MarketBeat recorded 3 mentions for Lexicon Pharmaceuticals and 2 mentions for Novavax. Lexicon Pharmaceuticals' average media sentiment score of 0.74 beat Novavax's score of 0.56 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 13.9% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Novavax has a net margin of 38.14% compared to Lexicon Pharmaceuticals' net margin of -568.04%. Lexicon Pharmaceuticals' return on equity of -103.16% beat Novavax's return on equity.
Lexicon Pharmaceuticals currently has a consensus target price of $3.67, suggesting a potential upside of 300.33%. Novavax has a consensus target price of $17.00, suggesting a potential upside of 151.48%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Novavax.
Summary
Lexicon Pharmaceuticals and Novavax tied by winning 8 of the 16 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 7/3/2025 by MarketBeat.com Staff
